Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias

European Journal of Neuroscience

Volumn 33, Issue 10, 2011, Pages 1823-1831

  Riahi, Golnasim ^a,b   Morissette, Marc ^b   Parent, Martin ^c   Di Paolo, Thérèse ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Basal ganglia; Ketanserin; l Dopa; Parkinson's disease; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 HYDROXYINDOLEACETIC ACID; BESONPRODIL; CABERGOLINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CINGULATE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; FEMALE; HAPLORHINI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BIOGENIC AMINES; BRAIN; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; ERGOLINES; FEMALE; HUMANS; KETANSERIN; LEVODOPA; MACACA; PARKINSONIAN DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 79955948512     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2011.07675.x     Document Type: Article

References (63)

1. Bélanger, N., Grégoire, L., Hadj Tahar, A. & Bédard, P.J. (2003) Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord., 18, 1436-1441.
2. Bezard, E., Gross, C.E. & Brotchie, J.M. (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci., 26, 215-221.
3. Bhattacharyya, S., Raote, I., Bhattacharya, A., Miledi, R. & Panicker, M.M. (2006) Activation, internalization, and recycling of the serotonin 2A receptor by dopamine. Proc. Natl Acad. Sci. USA, 103, 15248-15253.
4. Bishop, C. & Walker, P.D. (2003) Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats. Neuroscience, 121, 649-657.
5. Bishop, C., Tessmer, J.L., Ullrich, T., Rice, K.C. & Walker, P.D. (2004) Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J. Pharmacol. Exp. Ther., 310, 687-694.
6. Bishop, C., Daut, G.S. & Walker, P.D. (2005) Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology, 49, 350-358.
7. Blanchet, P.J., Konitsiotis, S., Whittemore, E.R., Zhou, Z.L., Woodward, R.M. & Chase, T.N. (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther., 290, 1034-1040.
8. Bryant, H.U., Nelson, D.L., Button, D., Cole, H.W., Baez, M.B., Lucaites, V.L., Wainscott, D.B., Whitesitt, C., Reel, J., Simon, R. & Koppel, G.A. (1996) A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci., 59, 1259-1268.
9. Calon, F., Morissette, M., Rajput, A.H., Hornykiewicz, O., Bédard, P.J. & Di Paolo, T. (2003) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord., 18, 241-253.
10. Carlson, B.B., Wisniecki, A. & Salamone, J.D. (2003) Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology (Berl), 165, 229-237.
11. Carlsson, M.L., Martin, P., Nilsson, M., Sorensen, S.M., Carlsson, A., Waters, S. & Waters, N. (1999) The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J. Neural Transm., 106, 123-129.
12. Carta, M., Carlsson, T., Kirik, D. & Bjorklund, A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 130, 1819-1833.
13. Chase, T.N., Oh, J.D. & Konitsiotis, S. (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol., 247(Suppl 2), II36-42.
14. Chen, C.P., Alder, J.T., Bray, L., Kingsbury, A.E., Francis, P.T. & Foster, O.J. (1998) Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann. N Y Acad. Sci., 861, 288-289.
15. Cyr, M., Bosse, R. & Di Paolo, T. (1998) Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex. Neuroscience, 83, 829-836.
16. Darchen, F., Scherman, D., Laduron, P.M. & Henry, J.P. (1988) Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol. Pharmacol., 33, 672-677.
17. Farber, N.B., Hanslick, J., Kirby, C., McWilliams, L. & Olney, J.W. (1998) Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology, 18, 57-62.
18. Fox, S.H., Chuang, R. & Brotchie, J.M. (2009) Serotonin and Parkinson's disease: on movement, mood, and madness. Mov. Disord., 24, 1255-1266.
19. Frechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquin, M. & Del Rio, J. (2001) Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse, 39, 288-296.
20. Gardell, L.R., Vanover, K.E., Pounds, L., Johnson, R.W., Barido, R., Anderson, G.T., Veinbergs, I., Dyssegaard, A., Brunmark, P., Tabatabaei, A., Davis, R.E., Brann, M.R., Hacksell, U. & Bonhaus, D.W. (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther., 322, 862-870.
21. Goulet, M., Morissette, M., Grondin, R., Falardeau, P., Bédard, P.J., Rostene, W. & Di Paolo, T. (1999) Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse, 32, 153-164.
22. Gresch, P.J. & Walker, P.D. (1999) Synergistic interaction between serotonin-2 receptor and dopamine D1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat. Brain Res. Mol. Brain Res., 70, 125-134.
23. Groenewegen, H.J. & Uylings, H.B. (2000) The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog. Brain Res., 126, 3-28.
24. Hadj Tahar, A., Grégoire, L., Darre, A., Bélanger, N., Meltzer, L. & Bédard, P.J. (2004) Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis., 15, 171-176.
25. Hornykiewicz, O. (1975) Brain monoamines and parkinsonism. Natl. Inst. Drug Abuse Res. Monogr. Ser., 3, 13-21.
26. Huot, P., Johnston, T.H., Winkelmolen, L., Fox, S.H. & Brotchie, J.M. (2010) 5-HT(2A) receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiol. Aging, doi: [Epub ahead of print].
27. Ismaiel, A.M., Arruda, K., Teitler, M. & Glennon, R.A. (1995) Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding. J. Med. Chem., 38, 1196-1202.
28. Jenner, P. (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci., 9, 665-677.
29. Kish, S.J. (2003) Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv. Neurol., 91, 39-49.
30. Kish, S.J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.J., Guttman, M. & Furukawa, Y. (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain, 131, 120-131.
31. Kugaya, A., Epperson, C.N., Zoghbi, S., van Dyck, C.H., Hou, Y., Fujita, M., Staley, J.K., Garg, P.K., Seibyl, J.P. & Innis, R.B. (2003) Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am. J. Psychiatry, 160, 1522-1524.
32. Laprade, N., Radja, F., Reader, T.A. & Soghomonian, J.J. (1996) Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J. Neurosci., 16, 3727-3736.
33. Lucas, G. & Spampinato, U. (2000) Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem., 74, 693-701.
34. Martin, R.F. & Bowden, D.M. (2000) Primate Brain Maps: Structure of the Macaque Brain. Elsevier Science, Amsterdam.
35. Meco, G., Stirpe, P., Edito, F., Purcaro, C., Valente, M., Bernardi, S. & Vanacore, N. (2009) Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. J. Neural Transm., 116, 881-884.
36. Morissette, M., Dridi, M., Calon, F., Hadj Tahar, A., Meltzer, L.T., Bédard, P.J. & Di Paolo, T. (2006a) Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse, 60, 239-250.
37. Morissette, M., Dridi, M., Calon, F., Hadj Tahar, A., Meltzer, L.T., Bédard, P.J. & Di Paolo, T. (2006b) Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov. Disord., 21, 9-17.
38. Moses-Kolko, E.L., Berga, S.L., Greer, P.J., Smith, G., Cidis Meltzer, C. & Drevets, W.C. (2003) Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women. Fertil. Steril., 80, 554-559.
39. Navailles, S., Benazzouz, A., Bioulac, B., Gross, C. & De Deurwaerdere, P. (2010) High-frequency stimulation of the subthalamic nucleus and L-3, 4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci., 30, 2356-2364.
40. 2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-D-aspartate depolarization. Behav. Brain Res., 73, 273-275.
41. Newman-Tancredi, A., Cussac, D., Quentric, Y., Touzard, M., Verriele, L., Carpentier, N. & Millan, M.J. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J. Pharmacol. Exp. Ther., 303, 815-822.
42. Oh, J.D., Bibbiani, F. & Chase, T.N. (2002) Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol., 177, 557-564.
43. Olanow, C.W., Watts, R.L. & Koller, W.C. (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology, 56, S1-S88.
44. Parent, A. & Hazrati, L.N. (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev., 20, 91-127.
45. Pazos, A., Probst, A. & Palacios, J.M. (1987) Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 21, 123-139.
46. Pehek, E.A., Nocjar, C., Roth, B.L., Byrd, T.A. & Mabrouk, O.S. (2006) Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology, 31, 265-277.
47. Perez-Otano, I., Herrero, M.T., Oset, C., De Ceballos, M.L., Luquin, M.R., Obeso, J.A. & Del Rio, J. (1991) Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res., 567, 127-132.
48. Pifl, C., Schingnitz, G. & Hornykiewicz, O. (1991) Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience, 44, 591-605.
49. Porras, G., Di Matteo, V., Fracasso, C., Lucas, G., De Deurwaerdere, P., Caccia, S., Esposito, E. & Spampinato, U. (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology, 26, 311-324.
50. Rahman, S. & Neuman, R.S. (1993) Activation of 5-HT2 receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate. Eur. J. Pharmacol., 231, 347-354.
51. Roberts, C. (2006) ACP-103, a 5-HT2A receptor inverse agonist. Curr. Opin. Investig. Drugs, 7, 653-660.
52. Rodriguez, J.J., Garcia, D.R. & Pickel, V.M. (1999) Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. J. Comp. Neurol., 413, 219-231.
53. Samadi, P., Grégoire, L., Morissette, M., Calon, F., Hadj Tahar, A., Dridi, M., Bélanger, N., Meltzer, L.T., Bédard, P.J. & Di Paolo, T. (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging, 29, 1040-1051.
54. Sanchez, M.G., Estrada-Camarena, E., Bélanger, N., Morissette, M. & Di Paolo, T. (2010) Estradiol modulation of cortical, striatal and raphe nucleus 5-HT(1A) and 5HT(2A) receptors of female hemiparkinsonian monkeys after long-term ovariectomy. Neuropharmacology, 60, 642-652.
55. Schmidt, C.J., Sullivan, C.K. & Fadayel, G.M. (1994) Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3, 4-methylenedioxymethamphetamine. J. Neurochem., 62, 1382-1389.
56. Seeman, P. (1980) Brain dopamine receptors. Pharmacol. Rev., 32, 229-313.
57. Smith, L.A., Jackson, M.J., Hansard, M.J., Maratos, E. & Jenner, P. (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov. Disord., 18, 487-495.
58. Tamim, M.K., Samadi, P., Morissette, M., Grégoire, L., Ouattara, B., Levesque, D., Rouillard, C. & Di Paolo, T. (2010) Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology, 58, 286-296.
59. Taylor, J.L., Bishop, C., Ullrich, T., Rice, K.C. & Walker, P.D. (2006) Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology, 50, 761-768.
60. Vanover, K.E., Betz, A.J., Weber, S.M., Bibbiani, F., Kielaite, A., Weiner, D.M., Davis, R.E., Chase, T.N. & Salamone, J.D. (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav., 90, 540-544.
61. Wang, S., Zhang, Q.J., Liu, J., Wu, Z.H., Ali, U., Wang, Y., Chen, L. & Gui, Z.H. (2009) The firing activity of pyramidal neurons in medial prefrontal cortex and their response to 5-hydroxytryptamine-1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience, 162, 1091-1100.
62. Zakharov, V.V. & Iakhno, N.N. (2005) Cognitive dysfunction in patients with Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova, 105, 13-19. [in Russian]
63. Zhang, X., Andren, P.E. & Svenningsson, P. (2007) Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol. Behav., 92, 29-33.